Volume 26, Issue 9 pp. 1031-1035
Original Article

Peri-implant evaluation in type 2 diabetes mellitus patients: a 3-year study

Gerardo Gómez-Moreno

Corresponding Author

Gerardo Gómez-Moreno

Department of Special Care in Dentistry, Pharmacological Research in Dentistry, Periodontology and Implant Dentistry, Faculty of Dentistry, University of Granada, Granada, Spain

Corresponding author:

Prof. Gerardo Gómez-Moreno, DDS, MSc, PhD

Facultad de Odontología

Campus Universitario de Cartuja

Colegio Máximo s/n, E-18071 Granada, Spain

Tel.: +34 958 244085

Fax: +34 958 240908

e-mail: [email protected]

Search for more papers by this author
Antonio Aguilar-Salvatierra

Antonio Aguilar-Salvatierra

Department of Pharmacological Research in Dentistry, Faculty of Dentistry, University of Granada, Granada, Spain

Search for more papers by this author
Jerónimo Rubio Roldán

Jerónimo Rubio Roldán

Periodontology and Implant Dentistry, Faculty of Dentistry, Universidad de Granada, Granada, Spain

Search for more papers by this author
Javier Guardia

Javier Guardia

Department of Pharmacological Research in Dentistry, Faculty of Dentistry, University of Granada, Granada, Spain

Search for more papers by this author
Jordi Gargallo

Jordi Gargallo

Department of Dentistry, Faculty of Dentistry, Universitat Internacional de Catalunya, Barcelona, Spain

Search for more papers by this author
José Luis Calvo-Guirado

José Luis Calvo-Guirado

Department of Implant Dentistry, Implant Dentistry and Biomaterials, School of Medicine and Dentistry, University of Murcia, Murcia, Spain

Search for more papers by this author
First published: 31 March 2014
Citations: 86

Abstract

Objective

The aim of this study was to analyze the changes produced in peri-implant tissues in type 2 diabetes mellitus patients with different glycemia levels, measured by monitoring glycated hemoglobin A1c (HbA1c), over a period of 3 years following dental implant placement.

Materials and methods

Sixty-seven patients were divided into four groups according to their HbA1c levels: 21 patients in Group 1 (<6); 24 patients in Group 2 (6.1–8); and 11 patients in Group 3 (8.1–10) and Group 4 (>10.1). Each patient received one implant. All implants were placed in the anterior zone of the maxilla. The variables selected to assess the general state of patients' peri-implant health were as follows: probing depth, bleeding on probing, and marginal bone loss.

Results

Marginal bone loss was found to increase in relation to increases in HbA1c levels. Bleeding on probing showed statistically significant differences between groups. When the peri-implant area was probed, mean levels of bleeding varied from 0.43 in Group 1 at 1 year after implant surgery to 0.62 in Group 4 (= 0.042 between the four study groups). After the second year, greater bleeding on probing was observed in Group 4 (0.63) in comparison with groups with lower HbA1c levels. Peri-implant pocket depths presented values that were too low to be considered pathological and without statistically significant differences between the study groups.

Conclusion

Implant therapies for diabetic patients can be predictable, providing these patients fall within controlled ranges of glycemia over time, assessed by monitoring HbA1c levels.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.